• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨桥蛋白异构体 c 通过 NFATc2 介导的抑制钙诱导的 ROS 水平促进顺铂处理的 NSCLC 细胞的存活。

Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.

机构信息

School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, China.

Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.

出版信息

BMC Cancer. 2021 Jun 29;21(1):750. doi: 10.1186/s12885-021-08495-z.

DOI:10.1186/s12885-021-08495-z
PMID:34187410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8243455/
Abstract

BACKGROUND

Tumor microenvironment (TME) critically contributed to the malignant progression of transformed cells and the chemical responses to chemotherapy reagents. Osteopontin (OPN) is a secretory onco-protein with several splicing isoforms, all of which were known to regulate tumor growth and able to alter cell-cell or cell-TME communication, however, the exact role and regulation of the OPN splicing isoforms was not well understood.

METHODS

In this study, the effects of conditioned medium from the culture of OPN splicing isoforms overexpressing cells on cell functions were evaluated. The methods of nuclear calcium reporter assays and subcellular distribution of nuclear factor of activated T cells c2 (NFATc2) assays were used to investigate the molecular mechanism underlining the roles of OPN splicing isoforms.

RESULTS

We found that the survival of NSCLC cells treated with cisplatin was increased by secretory OPNc in the condition medium, where reduction of apoptosis by OPNc was associated with the activation of cellular calcium signals and subsequent nuclear translocation of NFATc2.

CONCLUSIONS

The results revealed a mechanism of OPN and downstream signal for tumor cells to survive in chemo-stressed TME, which emphasized the importance of secretory proteins in alternative splicing isoforms. Our study not only demonstrated the importance of OPN neutralization for anti-tumor effects, but also implied that modulation in calcium/NFATc2/ROS axis could be a novel approach for improving the long-term outcome of NSCLC treatment.

摘要

背景

肿瘤微环境(TME)对转化细胞的恶性进展和化学治疗试剂的化学反应起着至关重要的作用。骨桥蛋白(OPN)是一种具有多种剪接异构体的分泌癌蛋白,所有这些异构体都被认为可以调节肿瘤生长,并能够改变细胞-细胞或细胞-TME 的通讯,但 OPN 剪接异构体的确切作用和调控机制尚不清楚。

方法

在这项研究中,评估了过表达 OPN 剪接异构体细胞培养的条件培养基对细胞功能的影响。使用核钙报告基因检测和激活 T 细胞核因子 c2(NFATc2)亚细胞分布检测方法,研究了 OPN 剪接异构体作用的分子机制。

结果

我们发现,顺铂处理的 NSCLC 细胞的存活率因条件培养基中的分泌型 OPNc 而增加,OPNc 通过减少细胞凋亡与细胞钙信号的激活和随后的 NFATc2 核转位有关。

结论

这些结果揭示了 OPN 及其下游信号在肿瘤细胞在化疗应激的 TME 中存活的机制,强调了分泌蛋白在剪接异构体中的重要性。我们的研究不仅证明了中和 OPN 对抗肿瘤作用的重要性,还暗示钙/NFATc2/ROS 轴的调节可能是改善 NSCLC 治疗长期疗效的一种新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/f61cfd3c54cb/12885_2021_8495_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/f9589bc60b1e/12885_2021_8495_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/e644599c6d55/12885_2021_8495_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/fc3903c1c834/12885_2021_8495_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/3da5904b37dd/12885_2021_8495_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/4f241e953e76/12885_2021_8495_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/f61cfd3c54cb/12885_2021_8495_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/f9589bc60b1e/12885_2021_8495_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/e644599c6d55/12885_2021_8495_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/fc3903c1c834/12885_2021_8495_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/3da5904b37dd/12885_2021_8495_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/4f241e953e76/12885_2021_8495_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcaa/8243455/f61cfd3c54cb/12885_2021_8495_Fig6_HTML.jpg

相似文献

1
Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.骨桥蛋白异构体 c 通过 NFATc2 介导的抑制钙诱导的 ROS 水平促进顺铂处理的 NSCLC 细胞的存活。
BMC Cancer. 2021 Jun 29;21(1):750. doi: 10.1186/s12885-021-08495-z.
2
Epigenetic regulation of osteopontin splicing isoform c defines its role as a microenvironmental factor to promote the survival of colon cancer cells from 5-FU treatment.骨桥蛋白剪接异构体c的表观遗传调控决定了其作为一种微环境因子的作用,可促进结肠癌细胞在5-氟尿嘧啶治疗下的存活。
Cancer Cell Int. 2020 Sep 14;20:452. doi: 10.1186/s12935-020-01541-z. eCollection 2020.
3
Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.非小细胞肺癌中骨桥蛋白同工型的功能异质性。
J Thorac Oncol. 2010 Oct;5(10):1516-23. doi: 10.1097/JTO.0b013e3181eba6bd.
4
Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.骨桥蛋白-c 和骨桥蛋白-b 拼接异构体在前列腺癌细胞中发挥促肿瘤作用。
Prostate. 2012 Nov;72(15):1688-99. doi: 10.1002/pros.22523. Epub 2012 Apr 11.
5
Osteopontin-c splicing isoform contributes to ovarian cancer progression.骨桥蛋白剪接异构体促进卵巢癌进展。
Mol Cancer Res. 2011 Mar;9(3):280-93. doi: 10.1158/1541-7786.MCR-10-0463. Epub 2011 Jan 24.
6
Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.采用免疫亲和捕获和靶向质谱法鉴定和定量肺癌患者血浆中的骨桥蛋白剪接变体。
Biomarkers. 2012 Mar;17(2):125-33. doi: 10.3109/1354750X.2011.643485. Epub 2011 Dec 22.
7
Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer.骨桥蛋白剪接变异体在人胃癌中的独特预后价值和细胞功能。
Cells. 2021 Jul 19;10(7):1820. doi: 10.3390/cells10071820.
8
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.骨桥蛋白和血小板反应蛋白-1在促进原发性切除非小细胞肺癌的肿瘤侵袭性方面发挥相反作用。
BMC Cancer. 2016 Jul 15;16:483. doi: 10.1186/s12885-016-2541-5.
9
Osteopontin is a prognostic biomarker in non-small cell lung cancer.骨桥蛋白是非小细胞肺癌中的一种预后生物标志物。
BMC Cancer. 2013 Nov 11;13:540. doi: 10.1186/1471-2407-13-540.
10
NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma.NFATc2 通过 NFATc2/SOX2/ALDH 轴增强肺腺癌的肿瘤起始表型。
Elife. 2017 Jul 24;6:e26733. doi: 10.7554/eLife.26733.

引用本文的文献

1
Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis.表皮生长因子受体(EGFR)酪氨酸激酶抑制剂治疗后进展的晚期EGFR突变非小细胞肺癌患者不同治疗方案的疗效和安全性:一项系统评价和网状荟萃分析
Ther Adv Med Oncol. 2025 May 19;17:17588359251338046. doi: 10.1177/17588359251338046. eCollection 2025.
2
Identification of protein biomarkers associated with congenital diaphragmatic hernia in human amniotic fluid.鉴定与人类羊水先天性膈疝相关的蛋白质生物标志物。
Sci Rep. 2023 Sep 19;13(1):15483. doi: 10.1038/s41598-023-42576-2.
3

本文引用的文献

1
Epigenetic regulation of osteopontin splicing isoform c defines its role as a microenvironmental factor to promote the survival of colon cancer cells from 5-FU treatment.骨桥蛋白剪接异构体c的表观遗传调控决定了其作为一种微环境因子的作用,可促进结肠癌细胞在5-氟尿嘧啶治疗下的存活。
Cancer Cell Int. 2020 Sep 14;20:452. doi: 10.1186/s12935-020-01541-z. eCollection 2020.
2
Alteration in the sensitivity to crizotinib by Na/H exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers.钠/氢交换体调节因子 1 的亚细胞定位改变可导致其对克唑替尼敏感性的变化,这在 ALK 阳性肺癌中存在。
BMC Cancer. 2020 Mar 12;20(1):202. doi: 10.1186/s12885-020-6687-9.
3
Osteopontin as a Biomarker in Chronic Kidney Disease.
骨桥蛋白作为慢性肾脏病的生物标志物
Biomedicines. 2023 May 4;11(5):1356. doi: 10.3390/biomedicines11051356.
4
Meta-analysis of Osteopontin splice variants in cancer.癌症中骨桥蛋白剪接变异体的荟萃分析。
BMC Cancer. 2023 Apr 24;23(1):373. doi: 10.1186/s12885-023-10854-x.
5
Chromatin and Cancer: Implications of Disrupted Chromatin Organization in Tumorigenesis and Its Diversification.染色质与癌症:染色质组织紊乱在肿瘤发生及其多样化中的影响
Cancers (Basel). 2023 Jan 11;15(2):466. doi: 10.3390/cancers15020466.
6
Periostin Augments Vascular Smooth Muscle Cell Calcification via β-Catenin Signaling.骨粘连蛋白通过β-连环蛋白信号增强血管平滑肌细胞钙化。
Biomolecules. 2022 Aug 21;12(8):1157. doi: 10.3390/biom12081157.
Osteopontin in Bone Metabolism and Bone Diseases.
骨代谢与骨疾病中的骨桥蛋白
Med Sci Monit. 2020 Jan 30;26:e919159. doi: 10.12659/MSM.919159.
4
Bavachin Protects Human Aortic Smooth Muscle Cells Against -Glycerophosphate-Mediated Vascular Calcification and Apoptosis Activation of mTOR-Dependent Autophagy and Suppression of -Catenin Signaling.补骨脂素保护人主动脉平滑肌细胞免受甘油磷酸介导的血管钙化和细胞凋亡——mTOR依赖性自噬的激活及β-连环蛋白信号通路的抑制
Front Pharmacol. 2019 Dec 19;10:1427. doi: 10.3389/fphar.2019.01427. eCollection 2019.
5
Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells.由RUNX2调控的增强型骨桥蛋白剪接依赖于组蛋白去乙酰化酶,并诱导非小细胞肺癌细胞的侵袭表型。
Cancer Cell Int. 2019 Nov 21;19:306. doi: 10.1186/s12935-019-1033-5. eCollection 2019.
6
OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.骨桥蛋白通过激活 RON 酪氨酸激酶促进非小细胞肺癌细胞的侵袭。
Sci Rep. 2019 Dec 2;9(1):18101. doi: 10.1038/s41598-019-54843-2.
7
Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion.NFATC1 在 PIM1 靶位的磷酸化对于其促进前列腺癌细胞迁移和侵袭的能力至关重要。
Cell Commun Signal. 2019 Nov 15;17(1):148. doi: 10.1186/s12964-019-0463-y.
8
A Generic Method for Fast and Sensitive Detection of Adeno-Associated Viruses Using Modified AAV Receptor Recombinant Proteins.一种使用改良的 AAV 受体重组蛋白快速灵敏检测腺相关病毒的通用方法。
Molecules. 2019 Nov 3;24(21):3973. doi: 10.3390/molecules24213973.
9
Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression.靶向肿瘤微环境抑制肿瘤的最新进展。
Int J Mol Sci. 2019 Sep 23;20(19):4719. doi: 10.3390/ijms20194719.
10
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗:综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.